WAAREEENER — Deck
India's largest solar PV module manufacturer with 13 GW installed capacity and 21% domestic market share, now investing $2.1B+ to integrate backward into cells, wafers, batteries, and US manufacturing.
Margin durability hinges on cell scarcity — the market is pricing module overcapacity, not the real bottleneck.
- DCR premium is widening, not compressing. Domestic-content modules sell at $0.25–0.28/Wp versus $0.15–0.16/Wp for non-DCR — a 60–70% spread that nearly doubled in early 2026. This premium funds the entire margin step-up from 14% to 25% OPM. It persists only as long as domestic cell capacity is scarce.
- Cell capacity ≠ module capacity. India has 210 GW of announced module capacity against 45–50 GW demand — but only 27–30 GW of operational cell capacity. Consensus treats all capacity equally. The DCR premium is a cell bottleneck, and cell commissioning takes 18–24 months longer than module line installation.
- ALMM-II deepens the bottleneck. From June 2026, all government solar projects require domestically manufactured cells — expanding DCR-eligible demand from 3–4 GW to 10–15 GW annually. If less than 40 GW of cell capacity is operational by H1 FY28, the scarcity thesis holds and 25% margins persist.
Revenue grew 7× in five years with margins expanding from 4% to 25% — but every dollar of cash is being reinvested.
Margin expansion is structural: backward integration into 5.4 GW of solar cells unlocks DCR premium pricing, and US manufacturing adds 60–70% higher module realizations. Cash conversion is exceptional — operating cash flow has exceeded net income every year since FY22, with a negative accrual ratio of −7.9%. But $796M of FY25 investing outflows swamped $370M of operating cash. For the $10.7B market cap to hold, FCF must inflect positive by FY28.
The 126% US tariff locks out every Indian competitor — Waaree is the sole beneficiary.
- Only Indian manufacturer on US soil. The 1.6 GW Brookshire, Texas facility — operational since January 2025 — earns IRA manufacturing credits of 7¢/Wp and sells at US realizations of $0.24–0.25/Wp, roughly 60–70% above domestic Indian prices. Expanding to 3–5 GW via the Meyer Burger acquisition.
- Tariff as competitive moat. The February 2026 preliminary CVD of 126% on Indian solar imports makes India-to-US exports unviable for every peer — Premier Energies, Vikram Solar, Emmvee — none have US production. If the final determination confirms rates above 50%, Waaree monopolizes Indian-origin US solar manufacturing.
- Narrative has pivoted. US export revenue flipped from 60% to 21% of the mix over 12 months. Management reframed this as 'manufacture where you sell' — credible given the Texas plant, but Meyer Burger integration during a seven-vertical capex cycle adds execution risk.
$2.1B+ across seven verticals simultaneously — the largest bet in Indian solar history.
Before. Through FY23, Waaree was a module assembler with 12 GW capacity, buying cells from China, earning 4–5% operating margins, and generating $85M of free cash flow. Capital-light, high-throughput, low-complexity.
Pivot. The October 2024 IPO raised $518M and management immediately deployed it — plus debt — across cells (5.4 GW), ingots/wafers (10 GW planned), US manufacturing (1.6 GW), battery storage (20 GWh by FY28), inverters, transformers, and green hydrogen. ROCE fell from 52% in FY22 to 35% in FY24 as capital deployed faster than it earned.
Today. The cell factory is working — 80% daily utilization, 25% margins. But batteries, inverters, and hydrogen have zero track record. CEO and CFO were both replaced in March 2026 — internal promotions, but two C-suite changes mid-capex-cycle warrants monitoring. If even half of the program earns returns above cost of capital, the platform thesis validates. If ROCE falls to 15%, it was diworsification.
Three catalysts resolve today — and two more within six months.
- Q4 FY26 results (today, April 29). Nine-month EBITDA of $462M implies Q4 needs $124–178M to meet $586–640M guidance — Q3 alone delivered $206M. Watch cell utilization quarterly average and FY27 EBITDA guidance. If full-year EBITDA exceeds $693M, consensus targets of ~$37 are stale.
- QIP / fund raising (today). Board considers equity issuance via QIP, GDR, or FCCB. Under $320M at a premium funds high-return capex without material dilution on a 287M share base. Above $533M at or below current price signals the capex program is outrunning internal accruals.
- US AD/CVD final determination (July–October 2026). The 126% preliminary rate is not final. Confirmed above 50% cements Waaree's US moat. Below 30% reopens the channel for Indian competitors and narrows Waaree's advantage.
Lean long, wait for confirmation — near-term earnings are real, but DCR margin durability is unproven.
- For. Q3 FY26 EBITDA of $206M annualizes 28% above guidance upper bound. Cash quality is among the best in Indian industrials — 1.9× CFO/NI over three years, negative accrual ratio, negative working capital days. At 26× trailing earnings, Waaree trades at a 61% discount to the sector P/E of 67×.
- For. US manufacturing locks out every Indian peer from the highest-margin export market. DCR cell scarcity — 27 GW operational vs 210 GW module — protects domestic pricing. FII ownership surged 10× to 7.06% in twelve months.
- Against. ROCE halved from 52% to 35% as $2.1B+ of capex deploys before earning returns. FCF turned negative. D/E doubled to 0.26× in six months. Seven verticals simultaneously — cells, wafers, batteries, inverters, transformers, hydrogen, US expansion — with no track record in five of them.
- Against. 140 GW of announced Indian cell capacity vs 50–70 GW demand threatens to eliminate the DCR scarcity premium within 18 months. If the $0.09–0.10/Wp spread compresses to zero, margins revert from 25% to 10–12% and the $10.7B market cap requires a fundamentally different earnings base.
Watchlist to re-rate: Q4 FY26 cell utilization quarterly average (above 70% confirms bull); US AD/CVD final determination July–October 2026 (above 50% cements moat); quarterly FCF inflection by H2 FY27.